| Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. | |
| | |
MedLine Citation:
|
PMID: 12042579 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: There is increasing concern in regard to the possible long-term adverse effects of postnatal dexamethasone treatment in preterm infants. The purpose of this study was to assess growth and neurodevelopmental outcome in preterm infants at high risk of chronic lung disease (CLD), treated with early (<96 hours) postnatal dexamethasone. DESIGN: Three-year follow-up data of physical growth and neurodevelopmental outcome of preterm infants enrolled in a controlled trial to study the effectiveness of early postnatal dexamethasone administration for the prevention of CLD were reviewed. The original trial included 25 treated neonates who received dexamethasone intravenously from the fourth day of life for 7 days (0.5 mg/kg/d for the first 3 days, 0.25 mg/kg/d the next 3 days, and 0.125 mg/kg/d on the seventh day), and 25 untreated neonates as controls. Forty-five surviving infants (22 untreated and 23 treated) completed the 3-year follow-up. RESULTS: At the end of follow-up, infants pertaining to both study groups had similar values for body weight, height, and head circumference, and a similar incidence of infants with anthropometrics data below the third percentile. Moreover, no differences were detected between the groups in regard to incidence of major cranial ultrasound abnormalities, cerebral palsy, major neurosensory impairment or IQ scores, and distribution. CONCLUSIONS: Early (<96 hours) postnatal dexamethasone administration at the doses employed in this study did not impair physical or neurodevelopmental outcome in preterm infants at high risk of CLD. However, the small sample size of our study was not tailored to look for long-term outcomes and our results are not in agreement with those of larger trials and systematic reviews. The real risks of postnatal dexamethasone administration could be definitely assessed only when more well-designed trials using long-term neurodevelopmental assessment as the primary outcome will be reported. |
| | |
Authors:
|
Costantino Romagnoli; Enrico Zecca; Rita Luciano; Giulia Torrioli; Giuseppe Tortorolo |
Related Documents
:
|
11381409 - Left-lung-collapse bronchial deformation in giant omphalocele. 17983879 - Adjunctive therapies in chronic lung disease: examining the evidence. 6542209 - Lung perforation by chest tubes in the neonate. 3794869 - Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infan... 12200909 - Body composition in infants with chronic lung disease after treatment with dexamethasone. 7000439 - A method of estimating the functional residual capacity of infants with respiratory dis... 2041539 - Trends in fertility and infant and maternal health--united states, 1980-1988. 21478759 - Oligosaccharides in 4 different milk groups, bifidobacteria, and ruminococcus obeum. 15725359 - Does angiotensin-1 converting enzyme genotype influence motor or cognitive development ... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Pediatrics Volume: 109 ISSN: 1098-4275 ISO Abbreviation: Pediatrics Publication Date: 2002 Jun |
Date Detail:
|
Created Date: 2002-06-03 Completed Date: 2002-07-15 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0376422 Medline TA: Pediatrics Country: United States |
Other Details:
|
Languages: eng Pagination: e85 Citation Subset: AIM; IM |
Affiliation:
|
Division of Neonatology, Department of Pediatrics, Catholic University of the Sacred Heart, Rome, Italy. cromagnoli@rm.unicatt.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
administration & dosage,
pharmacology,
therapeutic use* Child Development / drug effects*, physiology* Child, Preschool Chronic Disease Confidence Intervals Developmental Disabilities / prevention & control Dexamethasone / administration & dosage, pharmacology, therapeutic use* Drug Administration Schedule Follow-Up Studies Humans Infant Infant, Newborn Infant, Premature, Diseases / drug therapy* Lung Diseases / prevention & control* Odds Ratio Outcome Assessment (Health Care) Patient Readmission |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 50-02-2/Dexamethasone |
| Comments/Corrections | |
Comment In:
|
Pediatrics. 2002 Jun;109(6):1168-9
[PMID:
12042559
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy.
Next Document: Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Ind...